At the Chen Lab, we seek to uncover fundamental principles of G protein–coupled receptor (GPCR) signaling and harness these insights to develop transformative therapies for cancer and metabolic diseases.

GPCRs represent one of the largest and most therapeutically relevant families of signaling proteins. Our research aims to redefine how GPCR-driven networks contribute to cancer initiation, tumor progression, obesity, and diabetes. By integrating molecular pharmacology, functional genomics, and translational science, we bridge fundamental discovery with therapeutic innovation.

Using advanced cell-based systems, genetically engineered mouse models, and genome-scale functional approaches, we dissect signaling pathways that shape disease biology, identify shared vulnerabilities that enhance therapeutic efficacy, and uncover previously unrecognized roles of regulatory proteins such as WDR26 and RACK1 in cancer progression and glucose metabolism.

Through rigorous science and collaborative innovation, our mission is to translate mechanistic insights into meaningful clinical impact.